Amarantus Bioscience Holdings Inc (AMBS)

[MUKA1]

Posted April 1st...Worth reading again..
"Ceregene's clinical results could be great news for MANF/AMBS!
I believe that they are expected to be out this month.

It would mean that Ceregene has solved the question of delivery method to the brain! That's where Cogane failed..... Their GDNF factor was orally administered and failed to deliver behavioral improvements along with the clinical improvements..

If Ceregene's trials with neurturin yield real measurable behavioral improvements...it could be a great sign for the success of MANF.

As I understand it neurturin is of the GDNF family(per Wiki)....And since much of AMBS's latest tests have proven how MANF is yielding better results that the GDNF treatments... it would seem logical to me to test MANF in the same manner to compare levels of behavioral improvement."

Ceregene results out...not good for neurturin...maybe game changing for MANF.
https://www.michaeljfox.org/foundation/news-detail.php?news-in-context-second-phase-trial-of-cere-120-yields-disappointing-results
"Two other trophic factors in pre-clinical development for PD are CDNF (conserved dopamine neurotrophic factor) and MANF (mesencephalic astrocyte-derived neurotrophic factor). Both have been shown to have interesting effects in a laboratory setting. It's possible that down the road, either of these could prove to be as good, or even better, than GDNF or neurturin, but for now we just don't know. The research is yet to be done. The scientific community currently knows more about CDNF than it does MANF. Ongoing pursuit of both is warranted."